hepurposeofthisreportwastoupdatethe2006InternationalLeagueAgainstEpilepsy(ILAE)reportandidentifythelevelofevidenceforlong-termefficacyoreffectivenessforantiepilepticdrugs(AEDs)asinitialmonotherapyforpatientswithnewlydiagnosedoruntreatedepilepsy.AllapplicablearticlesfromJuly2005untilMarch2012wereidentified,evaluated,andcombinedwiththepreviousysis(Glauseretal.,2006)toprovideacomprehensiveupdate.
Thepriorysismethodologywasutilizedwiththreemodifications:(1)thedetectablenoninferiorityboundaryapproachwasdroppedandbothfailedsuperioritystudiesandprespecifiednoninferioritystudieswereyzedusinganoninferiorityapproach,(2)thedefinitionofanadequatecomparatorwasclarifiedandnowincludesanabsoluteminimumpointestimateforefficacy/effectiveness,and(3)therelationshiptablebetweenclinicaltrialratings,levelofevidence,andconclusionsnolongerincludesarecommendationcolumntoreinforcethatthisreviewofefficacy/evidenceforspecificseizuretypesdoesnotimplytreatmentrecommendations.
Thisevidencereviewcontainsoneclarification:ThecommissionhasdeterminedthatclassIsuperioritystudiescanbedesignedtodetectuptoa20?solute(ratherthanrelative)differenceinthepointestimateofefficacy/effectivenessbetweenstudytreatmentandcomparatorusinganintent-to-treatysis.SinceJuly,2005,threeclassIrandomizedcontrolledtrials(RCT)and11classIIIRCTshebeenpublished.Thecombinedysis(1940-2012)nowincludesatotalof64RCTs(7withclassIevidence,2withclassIIevidence)and11meta-yses.
Newefficacy/effectivenessfindingsincludethefollowing:levetiracetamandzonisamidehelevelAevidenceinswithpartialonsetseizuresandbothethosuximideandvalproicacidhelevelAevidenceinchildrenwithchildhoodabsenceepilepsy.
Therearenomajorchangesinthelevelofevidenceforanyothersubgroup.LevetiracetamandzonisamidejoincarbamazepineandphenytoinwithlevelAefficacy/effectivenessevidenceasinitialmonotherapyforswithpartialonsetseizures.AlthoughethosuximideandvalproicacidnowhelevelAefficacy/effectivenessevidenceasinitialmonotherapyforchildrenwithabsenceseizures,therecontinuestobeanalarminglackofwelldesigned,properlyconductedepilepsyRCTsforpatientswithgeneralizedseizures/epilepsiesandinchildreningeneral.
Thesefindingsreinforcetheneedformulticenter,multinationaleffortstodesign,conduct,andyzefutureclinicallyrelevantadequatelydesignedRCTs.Whenselectingapatient'sAED,allrelevantvariablesandnotjustefficacyandeffectivenessshouldbeconsidered.
查看信源地址
编辑:jiang下一页:癫痫治疗障碍仍难以克服
- 2022-04-262013年国际抗癫痫联合会抗癫痫解毒使用指南
- 2022-04-21抑郁症孕妇使用抗抑郁症药物会增加流产风险吗?
- 2022-04-13Circ Ep:左室肥厚高血压患者新发房颤增加SCD风险
- 2022-04-12Diabetes Obes Metab:恩格列净对肝脂肪变性和纤维化标志物的影响及其与心肾结局的关系
- 2022-04-11月经性癫痫患者妊娠期癫痫控制更好
- 2022-04-11【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- Diabetes Obes Metab:恩格列净对肝脂肪变性和纤维化标志物的影响及其与心肾结局的关系
- 月经性癫痫患者妊娠期癫痫控制更好
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- 癫痫治疗障碍仍难以克服
- 2013国际抗癫痫联合会抗癫痫药用指南
- 上海率先探索异地就医门诊费直接结算
- 抗癫痫药物预防新发癫痫:任重而道远
- 2016AAN:神经专家发表了有前途的专业见解
- 癫痫需要如何诊断?
- 癫痫猝死:凶手是谁?
- 癫痫患者停药问题解决了吗?最新的预测模型已经发布!
- 羊角病能生孩子吗?
- 被WHO推荐,IVD国产替代品在结核病诊断领域取得了新的成果
- 心率多少正常 如何保持正常心率不变
- UCB的Vimpat癫痫新适应症在美国获批
- 延迟性癫痫患者中风预后较差
- 不注意这些问题,吃多少药都没用!
- 北京哪家癫痫医院排名好,成本低
- FDA警告怀孕期间使用丙戊酸钠药物
- GW制药Epidiolex治疗Dret综合征获得欧盟孤儿药资格
- 控制癫痫患者再次抽搐,不包括可选药物?
- 预测癫痫患者再入院风险
- 罕见病例:自发性颞极性扩张伴癫痫发作
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 20首款慢性肾脏病治疗药物Forxiga获得NICE推荐
- PLoS ONE:新的合成蛋白能快速激活免疫系统抵抗流感
- 最大限度癫痫病治疗的日常习惯
- 原发癫痫病能康复吗
- 为什么癫痫病久治不愈
- 怎么治继发性羊癫疯 羊癫疯疗法方法有什么
- 怎么用生物学的方法治疗癫痫病
- 全面性癫痫的先兆学术研究
- Circ Ep:腺苷实验可鉴别复发AF消融术时的隐匿传导静脉
- 癫痫病长时间发作怎么办
- 治疗癫痫病小发烧药物
- 治疗法癫痫病有特效药
- 羊癫疯治疗方法有有哪些 五个治疗方法有效果好
- 老人得了癫痫病有什么症状
- 卫材在法国推出一代抗癫痫药Fycompa